Showing 361-370 of 21407 results for "".
- Shifting Focus: Investigators Describe Changes to Pancreatic β Cell at Onset of Type 1 Diabeteshttps://reachmd.com/news/shifting-focus-investigators-describe-changes-to-pancreatic-cell-at-onset-of-type-1-diabetes/2457349/Therapeutic Targeting of Mechanistic Pathway Has The Potential to Slow Disease Progression In Mice and HumansBOSTON – About eight million people live with Type 1 diabetes (T1D) worldwide, a chronic autoimmune condition in which the body attacks and destroys its
- Weight Loss Intervention in People with Type 2 Diabetes Influences Cancer-Associated Proteinshttps://reachmd.com/news/weight-loss-intervention-in-people-with-type-2-diabetes-influences-cancer-associated-proteins/2456997/A weight loss intervention in people with type 2 diabetes was found to alter levels of cancer-related proteins, according to the findings of a new University of Bristol-led study. The study, published in eBioMedicine, is the first to show that weight loss in people recently diagnosed with di
- Increased Body and Abdominal Fat in Teenagers Can Lead to ‘Vicious Cycle’ Ending in Type 2 Diabeteshttps://reachmd.com/news/increased-body-and-abdominal-fat-in-teenagers-can-lead-to-vicious-cycle-ending-in-type-2-diabetes/2456891/High fat mass in adolescence causes insulin resistance, which can lead to a “vicious cycle” of worsening insulin resistance and obesity by young adulthood and increased risk of type 2 diabetes. These findings come from a study conducted in collaboration between Univ
- Orforglipron and Titrated Insulin Glargine in Type 2 Diabeteshttps://reachmd.com/news/orforglipron-titrated-insulin-glargine-t2d/2487416/Key Takeaways Greater HbA1c reductions were observed with each orforglipron dose than with placebo by week 40. Weight loss and smaller insulin dose increases were observed with orforglipron than with placebo by week 40. Clinically significant
- Orforglipron: A New Oral GLP-1 Receptor Agonist in Type 2 Diabetes Carehttps://reachmd.com/news/orforglipron-a-new-oral-glp-1-receptor-agonist-type-2-diabetes-care/2475779/As the management of type 2 diabetes evolves, orforglipron is emerging as an oral GLP-1 receptor agonist with promising potential for efficacy and convenience. For many clinicians, the challenge of treating type 2 diabetes lies in delivering robust glycemic control while respecting p
- Ultrasound Elastography Tracks Reversible Masseter Remodeling After BoNT-A Injectionshttps://reachmd.com/news/ultrasound-elastography-tracks-reversible-masseter-remodeling-after-bont-a-injections/2484690/Botulinum neurotoxin type A (BoNT-A) induces reversible changes in both masseter volume and elasticity, according to a new prospective study using ultrasound elastography (USE) to quantify structural adaptation post-injection. The findings, published ahead of print
- Diet Plus 14:10 Fasting Lowered HbA1c in Women with Type 2 Diabeteshttps://reachmd.com/news/diet-plus-1410-fasting-lowered-hba1c-in-women-with-type-2-diabetes/2488306/Key Takeaways In Indian women with type 2 diabetes, a 24-week lacto-vegetarian diet plus 14-hour time-restricted eating was associated with significantly lower HbA1c than usual diabetes care. Insulin resistance (HOMA-IR) and lipid measures also improved significantly
- FINE‑ONE: Finerenone Lowers Albuminuria But Raises Hyperkalemia in Type 1 Diabetes CKDhttps://reachmd.com/news/fineone-finerenone-lowers-albuminuria-but-raises-hyperkalemia-in-type-1-diabetes-ckd/2485964/A phase 3 abstract reports results of finerenone in adults with type 1 diabetes and chronic kidney disease, focusing on changes in albuminuria alongsid
- Rising Challenge: Early-Onset Type 2 Diabetes in Young Adults and Emerging Technologieshttps://reachmd.com/news/rising-challenge-early-onset-type-2-diabetes-in-young-adults-and-emerging-technologies/2475646/Rates of early-onset type 2 diabetes among young adults have nearly doubled globally; in Sweden, recent studies observ
- New Clues Into Hypoglycemia Awareness: Protein Levels May Signal Brain Adaptations in Type 1 Diabeteshttps://reachmd.com/news/new-clues-into-hypoglycemia-awareness-protein-levels-may-signal-brain-adaptations-in-type-1-diabetes/2484004/A recent proteomics study has identified a potential biomarker linked to impaired awareness of hypoglycemia (IAH), a dangerous complication of type 1 diabetes that leaves patients unable to sense when their blood glucose drops